Search
Royalty Pharma PLC
RPRXAdd to Watchlist
66.520USD
-0.660-0.98%
Close 11-02 16:00（ET）
38.25BMarket Cap
34.63P/E TTM
Royalty Pharma PLC (RPRX) Stock Price Target & Forecast
Analyst Rating
Based on 8 analysts giving stock ratings to Royalty Pharma PLC in the past month.
Buy
2 Strong Buy
6 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
63.476USD-2.07%
RPRX Analyst Recommendation Trends
In the current month, RPRX has received 6 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. RPRX average Analyst price target in the last month is 63.476.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2
2
3
3
3
3
3
3
6
6
6
6
6
6
6
6
0
0
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8
8
10
10
10
10
10
10
RPRX Analyst Rating for Peer Comparison
Updated: Nov 1, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Biogen Inc
BIIB
10
17
10
1
0
38
Amgen Inc
AMGN
4
9
19
3
1
36
Eli Lilly and Co
LLY
10
19
3
1
0
33
Vertex Pharmaceuticals Inc
VRTX
10
17
5
0
1
33
Alnylam Pharmaceuticals Inc
ALNY
5
18
9
0
0
32
AbbVie Inc
ABBV
8
18
6
0
0
32
Neurocrine Biosciences Inc
NBIX
13
14
4
0
0
31
Merck & Co Inc
MRK
7
15
9
0
0
31
Bristol-Myers Squibb Co
BMY
5
6
18
1
0
30
Gilead Sciences Inc
GILD
7
18
5
0
0
30
Financial Forecasting
Based on analysts' estimates, RPRX EPS is projected to reach 1.182 in FY2026Q3, following reported EPS of 0.040 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
1.33
1.21
1.28
1.18
1.52
Actual
0.50
0.67
0.04
--
--
Surprise
-62.29%
-44.36%
-96.85%
--
--
FAQs
What is Royalty Pharma PLC's expected revenue for the next quarter?
Royalty Pharma PLC's expected revenue is 796.53M.
What is Royalty Pharma PLC's price target?
Analysts forecast that Royalty Pharma PLC's price target is USD 63.48, with the highest forecast at USD 70.00 and the lowest forecast at USD 46.00.
How have Royalty Pharma PLCRPRX's recent earnings per share performed?
The market expectation was USD 0.04, while Royalty Pharma PLCRPRX's earnings per share (EPS) for the previous quarter was USD 0.67. EPS for the next quarter is expected at USD 1.18.
What is the analyst rating for Royalty Pharma PLC?
Based on the ratings of Royalty Pharma PLC's stock from 8 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.